These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9676754)

  • 1. Safety and tolerability of conversion from stable Sandimmun maintenance treatment to Sandimmun Neoral in patients with rheumatoid arthritis.
    Flipo RM; Emery P; Scott DG; Situnayake RD; Prowse PJ; James DW; Cawley MI; Whatmough I; Schmidt AG
    J Rheumatol; 1998 Jul; 25(7):1263-9. PubMed ID: 9676754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics.
    Anderson IF; Helve T; Hannonen P; Leirisalo-Repo M; Gilboe IM; Nissilä M; Keystone EC; Kraag GR; Bjørneboe O; Chalmers A; Dovland H; Mueller E; Richard F; Whatmough I; Schmidt AG; Kovarik JM
    J Rheumatol; 1999 Mar; 26(3):556-62. PubMed ID: 10090162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group.
    Yocum DE; Allard S; Cohen SB; Emery P; Flipo RM; Goobar J; Jayawardena S; Job-Deslandre C; Jubb RW; Krüger K; Lopes Vaz A; Manger B; Mur E; Nygaard H; Weiner SM; Rainer F; Sack MR; Schiff MH; Schnitzer TJ; Trigg LB; Whatmough I; Schmidt AG
    Rheumatology (Oxford); 2000 Feb; 39(2):156-64. PubMed ID: 10725065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis.
    Atakan N; Erdem C
    J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):240-6. PubMed ID: 9883436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis.
    Johns KR; Littlejohn GO
    J Rheumatol; 1999 Oct; 26(10):2110-3. PubMed ID: 10529125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoral--new cyclosporin for old?
    Somerville MF; Scott DG
    Br J Rheumatol; 1997 Oct; 36(10):1113-5. PubMed ID: 9374930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study.
    Altman RD; Schiff M; Kopp EJ
    J Rheumatol; 1999 Oct; 26(10):2102-9. PubMed ID: 10529124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis.
    Erkko P; Granlund H; Nuutinen M; Reitamo S
    Br J Dermatol; 1997 Jan; 136(1):82-8. PubMed ID: 9039300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abouzeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2252-7. PubMed ID: 18790206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy, tolerability and safety of cyclosporine for microemulsion in the treatment of active rheumatoid arthritis. Open study].
    Marcos JC; Maccagno A; Gutfraind E; Garsd A; Messina DO; Maldonado Cocco J; Battagliotti C; Onetti CM; Tate G; Venarotti HO; Grosman H; Díaz EA; Otero AB
    Medicina (B Aires); 2000; 60(4):435-40. PubMed ID: 11188947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: effects of treatment with cyclosporin A (Neoral).
    VanderBorght A; De Keyser F; Geusens P; De Backer M; Malaise M; Baeten D; Van den Bosch F; Veys EM; Raus J; Stinissen P
    J Rheumatol; 2002 Mar; 29(3):416-26. PubMed ID: 11908552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine.
    van den Borne BE; Landewé RB; Goei The HS; Rietveld JH; Zwinderman AH; Bruyn GA; Breedveld FC; Dijkmans BA
    J Rheumatol; 1998 Aug; 25(8):1493-8. PubMed ID: 9712089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients. International Kidney Biopsy Registry of Cyclosporin (Sandimmun) in Autoimmune Diseases.
    Br J Rheumatol; 1993 Mar; 32 Suppl 1():65-71. PubMed ID: 8448642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sandimmun-Neoral--a new quality of life for patients with severe systemic juvenile rheumatoid arthritis].
    Alekseeva EI; Shakhbazian IE
    Ter Arkh; 1999; 71(5):26-9. PubMed ID: 10399226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.